NJ-EXPERIC
27.2.2024 12:23:34 CET | Business Wire | Press release
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, announced its new facility in Dublin, Ireland, to support global clinical trials. The opening of this depot will expand the Company’s global footprint, increase the efficiency of its worldwide clinical trial supply services, and facilitate future growth.
At the forefront of this expansion effort is Experic's Vice President of Operations, Brian Fagan. "Experic is a company that listens to its customers,” shared the 25+ year clinical trial supply veteran. “When customers voiced their preference for more clinical trial supply services under the Experic umbrella – we listened - and made it a strategic priority to expand direct management of these services in Europe.”
The new Experic depot will do just that thanks to its geographical proximity to European markets and North America. The secure, 10,000 sq. ft. warehouse space will provide monitored storage and logistics services, including cold storage and re-labeling capabilities, for the rapid and reliable distribution of Investigational Medicinal Products (IMPs) and comparators for pharmaceutical companies conducting global clinical trials with investigator sites and patients across Europe. Opening in the second half of 2024, the depot activities will be carried out by local talent that is familiar with EU regulatory requirements, with the support of Experic’s expert project management team in the United States and the Company’s current Global Partner Depot Network.
This facility serves as the company's first physical expansion of business into the EU and will ultimately contribute to the efficiency and success of trial services.
If you would like to request a meeting with Experic at Clinical Trial Supply Europe in Barcelona next month, please go here.
About Experic:
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company, supports every phase of a product’s life cycle from conception to clinical and commercial scale, across a range of dosing and packaging formats. From our state-of-the-art, cGMP facility, we manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service. Learn more about our manufacturing and clinical trial supply services at expericservices.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227449218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz Delivers Record Nine-month Result of 14.1 Billion Euros and Raises 2026 Outlook12.11.2026 07:06:00 CET | Press release
3Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111915059/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 44.4 billion euros, an internal growth of 3.0 percent1. Excellent contribution from Asset Management and good internal growth in Property-Casualty. Operating profit rises 6.2 percent to 4.7 billion euros, driven by an outstanding result from the Asset Management segment, attributable to higher business volume and margins, and a strong contribution from Life/Health. Shareholders’ core net income increases 1.2 percent to 2.9 billion euros. Adjusted for offsetting measures following the sale of the stake in our Indian JVs, underlying growth is 3 percent. 9M 2026 Total business volume at 143.0 billion euros, an internal growth of 3.8 percent 1 , driven by excellent growth in Asset Management and good internal growth in Property-Casualty. Operating profit rises 7.8 percent to 14.1 bil
LTM Brings AI-Powered Quantum Error Mitigation to IBM Quantum Functions Catalog12.11.2026 06:30:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that AI-QEM, its proprietary AI-powered Quantum Error Mitigation capability, is now available in the IBM Quantum Functions Catalog. With this milestone, LTM becomes the first Global Systems Integrator (GSI) worldwide to publish a function in the catalog. The IBM Quantum Functions Catalog is an ecosystem of partner-built quantum software services that simplify quantum workflows and enable researchers and enterprises to run quantum experiments more efficiently for algorithm development and application prototyping. AI-QEM is available as a circuit function, allowing users of eligible IBM Quantum access plans to apply LTM's error mitigation capability directly within their Qiskit workflows. Quantum computers are inherently susceptible to noise and errors that can impact computational outcomes. While conventional error mitigation techniques often require additional circuit executions, quantum processing
Access Advance Announces New Effective Discount Rates for Its Multi-Codec Bridging Agreement, Starting on January 1, 202711.11.2026 20:18:00 CET | Press release
Access Advance LLC today announced that the Licensors of the HEVC Advance and VVC Advance Patent Pools have independently approved a two-step, phased reduction in the effective royalty discount available under the Multi-Codec Bridging Agreement (MCBA) for Licensees of both pools who sign the MCBA on or after January 1, 2027. Licensees that join both the HEVC Advance and VVC Advance Patent Pools and execute the MCBA on or before December 31, 2026, will secure the current MCBA rates, resulting in an effective discount of up to 50%. Licensees that sign on or after January 1, 2027 will receive a reduced discount as further described below. The MCBA is an administrative agreement, not a separate license, that lets Licensees of both HEVC Advance and VVC Advance Patent Pools pay a single, reduced royalty rate for products that include both HEVC and VVC codecs. Today the MCBA rate for a dual-codec product is the same as the VVC Advance single codec product rate; up to 50% of what a Licensee wo
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom